Date:	12/10/2022
Your Name:	Mariea Brady
Manuscript Title:	Diagnosing acute bone and joint infection in children: How does imaging alter the probability of infection?
Manuscript Number (if known):	BJJ-2022-1179.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None     Non	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None     Non	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board,	None     ■	

ring statement to indicate your agreeme	ent:
	ing statement to indicate your agreeme

Date: 15th December 2022 Your Name: Prof. Saul N. Faust

Manuscript Title: Diagnosing acute bone and joint infection in children: How does imaging alter the

probability of infection?

Manuscript number (if known): BJJ-2022-1179.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NIHR	Grant to support the running of the trial paid to University of Oxford
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	Pfizer	Clinical trial investigator on behalf of institution - no personal payments of any kind
	in item #1 above).	Sanofi	Clinical trial investigator on behalf of institution - no personal payments of any kind
		GSK	Clinical trial investigator on behalf of institution - no personal payments of any kind

		1&1	Clinical trial investigator on behalf of institution - no
		303	personal payments of any kind
		Merck	Clinical trial investigator on behalf of institution - no
			personal payments of any kind
		AstraZeneca	Clinical trial investigator on behalf of institution - no
			personal payments of any kind
		Valneva	Clinical trial investigator on behalf of institution - no
			personal payments of any kind
3	Royalties or licenses	None	
	,		
4	Consulting fees	J&J	Speaker on COVID booster vaccines to company internal
			symposium - no personal payments of any kind
		GSK-CureVac	Speaker on public funded COV-BOOST trial to company
			internal meeting- no personal payments of any kind
5	Payment or honoraria for	Moderna	Speaker at conference symptosium - participation paid
	lectures, presentations,		to INSTITUTION - not a personal fee
	speakers bureaus,	Novavax	Speaker at conference symptosium - participation paid
	manuscript writing or		to INSTITUTION - not a personal fee
	educational events	Oxford Immunotec	Speaker at conference symptosium - participation paid
			to INSTITUTION - not a personal fee
6	Payment for expert	None	·
	testimony		
	,		
7	Support for attending	None	
-	meetings and/or travel		
	,		
8	Patents planned issued or	None	
٥	Patents planned, issued or	None	
	pending		
9	Participation on a Data	Astra7anasa	fees for advisory board participation paid to
9	Participation on a Data	AstraZeneca	INSTITUTION - not a personal fee
	Safety Monitoring Board or Advisory Board	Medimmune	fees for advisory board participation paid to
	Advisory Board	Wediminale	INSTITUTION - not a personal fee
		Sanofi	fees for advisory board participation paid to
		Salloll	
		Pfizer	INSTITUTION - not a personal fee fees for advisory board participation paid to
		FIIZEI	INSTITUTION - not a personal fee
		Sogirus	fees for advisory board participation paid to
		Seqirus	INSTITUTION - not a personal fee
		Sandoz	fees for advisory board participation paid to
		Januuz	INSTITUTION - not a personal fee
		Morek	fees for advisory board participation paid to
		Merck	
		10.1	INSTITUTION - not a personal fee
		181	fees for advisory board participation paid to INSTITUTION - not a personal fee
10	Loadorchia or fiduciamurala	Chair of LIV NICE Consis	
10	Leadership or fiduciary role in other board, society,	Chair of UK NICE Sepsis	Expenses paid in line with NICE financial regulations.
	in other board, society,	(2014-16) and Lyme	

	committee or advocacy group, paid or unpaid	Disease (2016-18) Guidelines (adults and children)	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	12/15/2022
Your Name:	Dr Stuart Hartshorn
Manuscript Title:	Diagnosing acute bone and joint infection in children: How does imaging alter the probability of infection?
Manuscript Number (if known):	BJJ-2022-1179.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None     Non	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None     Non	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board,	None     ■	

ring statement to indicate your agreeme	ent:
	ing statement to indicate your agreeme

Date:	12/8/2022
Your Name:	Professor Amaka C Offiah
Manuscript Title:	Diagnosing acute bone and joint infection in children: How does imaging alter the possibility of infection?
Manuscript Number (if known):	BJJ-2-22-1179.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None None	Click the tab key to add additional rows.
	No time limit for this item.		
		Time frame: past 36 months	5
2	Grants or contracts from	□ None	
	any entity (if not	NIHR 134125	Payment to institution
	indicated in item	Research England/OfS	Payment to institution
	#1 above).	MRC MR/W01761X/1	Payment to institution
		NIHR 200725	Payment to institution
		MRC (Confidence in Concept) 7 2019	Payment to institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None	
4	Consulting fees	Alexion Ascendis AMRA BioMarin EnvisionIT Novo Nordisk	Payment to the author
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Mereo InfoMed	Payment to the author Payment to the author
6	Payment for expert testimony	□ None  Forensic Access Ltd  Foresight Ltd	Payment to company of which author is Director Payment to company of which author is Director
7	Support for attending meetings and/or travel	□ None  European Congress of Radiology  European Society of Paediatric Radiology	Reimbursement to author Reimbursement to author
8	Patents planned, issued or pending	None     Non	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Chair, European Society Paediatric Radiology Child Abuse Taskforce Convenor, Skeletal Dysplasia Group for Teaching and Research Chair, Sheffield Children's Hospital Scientific Advisory Committee Trustee: The Children's Hospital Charity, Notre Dame High School, Sheffield, A Rare Cause, RadReach	Unpaid Unpaid Unpaid Unpaid Unpaid
11	Stock or stock options	None None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None     ■	
13	Other financial or non-financial interests	☐ None  Managing Editor (outside the Americas) of the journal Pediatric Radiology	Payment to company of which author is Director
Plea	Please place an "X" next to the following statement to indicate your agreement:		
$\boxtimes$	☐ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	Tim Theologis  Diagnosing acute bone and joint infection in children: How does imaging alter the probability of infection?	
Your Name:		
Manuscript Title:		
Manuscript Number (if known):	BJJ-2022-1179.R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	□ None  The wider project on imaging in bone and joint infection in children (the PICBone study) is funded by the NIHR Health Technology Assessment grant: NIHR134125	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None     Non	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None     Non	
7	Support for attending meetings and/or travel	None     Non	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None     ■	
10	Leadership or fiduciary role in other board,	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid	President of the British Society for Children's Orthopaedic Surgery - BSCOS 2018-2020	
11	Stock or stock options	None None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None None	
Please place an "X" next to the following statement to indicate your agreement:			
$\boxtimes$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		